Investigational drug for advanced stomach cancer after second-line therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug for people with stomach or gastroesophageal junction cancer that has spread and has not responded to at least two previous treatments. The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that has spread or returned and has gotten worse after at least two previous treatments.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You have not had major surgery in the past 4 weeks, and you do not plan to have major surgery during the trial.
- You do not have untreated or rapidly worsening brain metastases that cause symptoms.
- You are not pregnant or breastfeeding, and you do not have severe allergies to the study drug or its components.
- You are mentally able to understand and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has grown after earlier treatment. It aims to see if adding these drugs can help shrink tumors or slow the disease.
Hear when a new Gastric Cancer (GC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.